KRYSTAL WEIAND: Open Payments
NPI 1073023016 · CHICAGO, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$599 in 35 payments from 13 companies in 2025. Trend: 2023 $1,237 · 2024 $282 · 2025 $599
Food & beverage: $599
| Company | Payments | Amount |
|---|---|---|
| Galderma Laboratories, L.P. | 17 | $258 |
| Janssen Biotech, Inc. | 3 | $69 |
| Novartis Pharmaceuticals Corporation | 2 | $39 |
| Lilly USA, LLC | 2 | $37 |
| Amgen Inc. | 2 | $35 |
| Regeneron Healthcare Solutions, Inc. | 1 | $33 |
| MAYNE PHARMA COMMERCIAL LLC | 2 | $29 |
| GENZYME CORPORATION | 1 | $24 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | 1 | $18 |
| Journey Medical Corporation | 1 | $18 |
Products named: NEMLUVIO, TREMFYA, DUPIXENT, TALTZ, OTEZLA, Rhapsido, Cabtreo, Bimzelx.
Industry payments across IL — which companies pay providers there.
